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LACK OF SEXUAL DIMORPHISM IN EFFECTS OF LOCAL ANESTHETICS  
LAURA CATHERINE PETISHNOK  
ABSTRACT 
 Research suggests biological sex differences may affect pain perception, however 
the difference in analgesic tolerance between male and females not been extensively 
studied. Therefore, here we studied the response of male and female Sprague-Dawley rats 
to prolonged duration local anesthetics; including conventional amino-amide anesthetics 
(bupivacaine), site 1 sodium channel blockers (tetrodotoxin) and a prolonged duration 
liposomal formulation (Exparel).  This study examined the incidence and duration of 
sensory and motor blockade; systemic side effects, as well as local neurotoxicity and 
myotoxicity in both male and female rodents in an in vivo model of sciatic nerve 
blockade. The data collected does not indicate a sexual dimorphism among the agents 
studied.   
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INTRODUCTION 
 
Pain is a universal phenomenon that is defined by the International Association 
for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience 
associated with active or potential tissue damage1.” Pain can be experienced in a wide 
range of contexts, from acute and chronic pain, which require analgesics (medications to 
relieve pain) to operative pain, in which anesthetics (medications that provide pain relief, 
hypnosis, and/or amnesia) are required. Despite the fact that pain is experienced by both 
men and women, female animals and female research subjects were historically excluded 
from scientific study under the rationale that the estrous cycle and hormonal fluctuation 
add confounding variables 2,3 This point was brought to light when a 1992 review article 
revealed that 45 of 100 journal articles published in a neuroscience journal failed to 
report the sex of their research subjects 4. Since then, the National Institutes of Health 
(NIH) has encouraged research applications (RFA: DE-97-003, 1997) and hosted 
research conferences, with a goal of promoting the study of sex-related differences within 
the context of pain research5. It is now the expectation of the NIH that scientists will 
account for the “possible role of sex as a biological variable in vertebrate animal and 
human studies,” and will provide “strong justification from the scientific literature, 
preliminary data, or other relevant justification when applications propose to study one 
sex.” 6 Upon the inclusion of female animal models and research participants, a number 
of studies suggest an underlying biological basis for differences in the perception of 
pain7–9. However, while males and females may experience pain differently, it is 
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currently unknown whether sex influences the response to medications aimed at 
eliminating pain, including local anesthetics.   
Pain and Pain Management  
Pain is the most common reason people seek medical attention. It is estimated that 
100 million Americans suffer from chronic pain, and that 39.5 million adults report 
having moderate to severe pain on all or nearly all days10. Systemic therapies for pain 
management, such as oral or intravenous treatments, have proven successful in reducing 
pain. However, their lack of specificity causes a high frequency of unwanted side effects. 
For example, extended use of acetaminophen can cause liver dysfunction, while daily use 
of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with potentially serious 
renal, gastrointestinal, and cardiovascular side effects. Recently highlighted by the opioid 
epidemic, opioid use is associated with side effects ranging from constipation, and 
itchiness, to sedation, addiction, and death from overdose11,12. In 2016, there were 42,249 
opioid related deaths in the United States, and opioid overdose deaths were five times 
higher in 2016 than they were in 199913. Many individuals are first exposed to opioids as 
part of their primary therapy for postoperative pain management.  Therefore, in an effort 
to decrease exposure to systemic opioids, clinical providers and medical scientists are 
seeking potential opioid alternatives for perioperative and chronic pain, including 
antidepressants, antispasmotic agents (benzodiazepines), membrane stabilizing agents 
(gabapentin and pregabalin), and increasing the use of perioperative local anesthetics14.  
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Local Anesthetics 
 Cocaine was the first local anesthetic introduced to clinical medicine as a topical 
anesthetic agent for the cornea in 188415. It was widely used until 1904, when an 
understanding of the physicochemical properties of local anesthetics 16 and their impact 
on potency, onset latency, and duration of action, enabled the development of synthetic 
local anesthetics. The first synthetic local anesthetic, procaine, was introduced in 1905 17. 
In 1943 lidocaine was synthesized, and it is still used clinically as the prototypic local 
anesthetic to which other drugs are compared17.  
The defining characteristics of local anesthetics are a lipophilic aromatic ring, a 
tertiary amine group (hydrophilic when protonated), and a connecting ester or amide 
linker. Conventional ester local anesthetics include cocaine, procaine, chloroprocaine, 
tetracaine, and benzocaine. Amide local anesthetics include lidocaine, bupivacaine, 
mepivcaine, etidocaine, prilocaine, ropivacaine, and articaine 15. Ester and amide local 
anesthetics differ in their mechanisms of metabolism. In addition, ester local anesthetics 
produce metabolites and are more likely to evoke an allergic reaction than amide local 
anesthetics17.   
Local anesthetics can be delivered via infiltration anesthesia (an injection 
throughout a tissue), peripheral nerve blockade (an injection deposited on or near a 
specific nerve leading to anesthesia of all innervated structures), or spinal and epidural 
blockade (nerve block on or around the spinal cord)18. Local anesthetics block nerve 
conduction by preventing flux of sodium ions across the nerve membrane through the 
inactivation (closing or blocking) of sodium channels. Blocking sodium flux prevents 
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depolarization of nerve fibers, stopping the conduction of nerve impulses17. In addition to 
the mechanism of action and pharmacokinetics of local anesthetics, the development of 
anesthesia is dependent on the properties of nerves, such that small diameter nerves are 
more susceptible to block than larger nerves and a myelinated nerve is more susceptible 
than an unmyelinated nerve17.  Clinically, the order of loss of nerve function is (1) pain, 
(2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone19.   
Local Anesthetics – Bupivacaine  
Bupivacaine was first synthesized in 1957 and is an amide local anesthetic that 
binds to the intracellular portion of voltage-gated sodium channels. In a 1996 study, it 
was found that the postoperative epidural administration of bupivacaine alone or in 
combination with morphine (an opiate) provided longer lasting analgesia than with 
morphine or saline controls. The addition of bupivacaine reduced patient pain scores, 
time to required administration of supplemental analgesic agent, and total number of 
supplemental doses of analgesic agent, demonstrating bupivacaine’s potential as an 
effective local anesthetic20. However, as the effective duration of block is relatively short, 
single bupivacaine injections are not suitable for the management of chronic or 
neuropathic pain. In order to achieve the desired duration of nerve blockade with 
bupivacaine, repeated injections or placement of indwelling catheters are necessary. 
Unfortunately, these approaches require skilled personnel for site specific injections, 
catheter placement, adjustment of drug levels, and monitoring of drug effects (intended 
and unintended)15.  
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One well-recognized unintended drug effect that is associated with local 
anesthetics is myotoxicity. Myotoxicity has been shown to develop in response to local 
anesthetics in a variety of settings, even following a single intramuscular injection 21–25.  
The development of myotoxicity, neurotoxicity, and other signs of systemic toxicity 
(respiratory distress, contralateral block) are often dependent on the route of drug 
administration. If delivered locally, at a normal therapeutic dose (2.5 to 7.5 mg per ml), 
conventional local anesthetics cause minimal changes in cardiac conduction, excitability, 
refractoriness, contractility, and peripheral vascular resistance, and the presence of 
adverse effects is limited to cases of accidental intravascular injection.25 If delivered 
systemically at high concentrations, conventional local anesthetics can cause hazardous 
side effects such as: cardiac arrhythmias (atrial-ventricular (AV) block and ventricular 
arrhythmias), cardiac arrest, neurotoxicity, and death25.  
Bupivacaine is therefore used locally, in a variety of clinical applications, at the 
concentration of 5 mg/ml (0.5%).  When used for peripheral nerve blocks, this dose has 
been shown to consistently establish effective, reversible nerve blockade that lasts 
approximately 150 minutes26. It was therefore determined that this was an ideal dose to 
choose in order to study if a sex-related response exists for conventional local anesthetics. 
As bupivacaine is standardly used in both male and female patients, it is critical to 
determine if the male and female response to the drug is different.  
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Prolonged Duration Local Anesthetics – Liposomal Bupivacaine (Exparel) 
Even though adjuvants (e.g epinephrine) have demonstrated a modest ability to 
extend the duration of local anesthetics, these drugs have a relatively short duration of 
nerve block 27 . As a result, there has been interest in developing advanced drug designs, 
such as drug depots and triggerable release particles, in order to extend local anesthetics’ 
duration of action. One method that has shown success is liposomal drug encapsulation.  
Liposomes are closed bilayer structures that are formed when phospholipids are placed in 
an aqueous environment 28.  Liposomes can vary in size, and can be classified as either 
unilamellar, multilamellar, or multivesicular membranes. The formation of liposomes 
from phospholipids results in a lipophilic environment between individual phospholipids, 
and a hydrophilic aqueous compartment located centrally and between concentric rings. 
Therefore, liposomes have the potential to partition either lipid-soluble or aqueous 
drugs28–31.  
Liposomal drug encapsulation generated particulate drug delivery systems have 
the potential to improve the therapeutic index (ratio between the dose that causes therapy 
and that which causes toxicity) of bupivacaine as liposomal local anesthetic 
encapsulation allows for a slow and controlled drug release, allowing the drug to have an 
effect until the entire payload has been deposited. As drug is released slowly, rather than 
at once (burst release), greater drug doses (that would normally be toxic) can be loaded 
into the liposomes and tolerated clinically. Encapsulating drug within liposomes may also 
reduce neurotoxicity that is associated with conventional local anesthetics 29–32. In that, it 
is well established that liposomes have been utilized for prolonged duration local 
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anesthesia without observing evidence of local neurotoxicity from in vitro studies, 
neurobehavioral testing, high-resolution microscopy, and gene expression analysis of 
dorsal root ganglia. Similarly, a study conducted in rabbits concluded that systemic 
toxicity (seizures and ventricular tachycardia) occurred following injection of 15.7 ± 2.5 
mg/kg of bupivacaine. However, when liposomal bupivacaine was used, 22.43 ± 2.63 
mg/kg was required to induce such side effects 33.  
Bupivacaine, in addition to other conventional local anesthetics, can also be easily 
encapsulated within polymeric particles as they form hydrogen bonds with the polymeric 
particles in an aqueous environment. Synthetic hydrophobic polymers, such as poly 
(lactic acid) (PLA), poly (glycolic acid) (PGA), and poly (lactic-co-glycolic acid) 
(PLGA), are frequently used in encapsulation34,35. For example, PLGA microspheres with 
a mean diameter ranging from 65 to 70 µm, loaded with bupivacaine, demonstrated four 
days of nerve block following skin incision in an animal model, extending the effect of 
0.5% bupivacaine by more than 20 fold36.  
 Despite large bodies of research related to prolonged duration local anesthetics, 
currently only one formulation of liposomal bupivacaine (Exparel) is approved for 
clinical use. Exparel is a sterile suspension of multivesicular liposomes using DepoFoam 
technology to release bupivacaine over several days. The DepoFoam system consists of 
multivesicular liposomes composed of hundreds to thousands of chambers per particle, 
resembling a “honeycomb-like” matrix33.  The anesthetic effect of Exparel has been 
measured in perianal infiltration in patients undergoing hemorrhoidectomy (in which 63 
male and 32 female patients were each treated with a dose of 300 mg of Exparel) 37, peri-
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metatarsal infiltration for bunionectomy (in which 22 men and 75 women were treated 
with 120 mg of Exparel) 38, surgical site infiltration for breast augmentation (66 female 
patients treated with 600 mg of Exparel) 39, and wound infiltration for knee arthroplasty 
(in which 13 men and 15 women were treated with 133 mg; 13 men and 12 women were 
treated with 266 mg, 11 men and 15 women were treated with 399 mg and 5 men and 20 
women were treated with 532 mg of Exparel)40. Patients from these studies reportedly 
remained opioid free for longer, and required less cumulative opioid dosing compared to 
saline placebo 37,38 . However, in a clinical trial directly comparing Exparel to 
bupivacaine and measuring time until supplemental analgesic is required, there was no 
statistically significant difference appreciated between those receiving the liposomal 
formulation and those receiving free drug39,40.  Exparel is indicated by the FDA for 
human use in both bunionectomy and hemmoroidectomy at the doses of 106 mg (8 mL) 
and 266 mg (20 mL), respectively.  It is notable, that all of the aforementioned clinical 
studies included both male and female patients; however, the data was combined rather 
than compared. To our knowledge, this is the first study that has investigated any sex-
related difference in block or systemic toxicity for this liposomal drug formulation.  
In an all-male rodent model of sciatic nerve blockade, Exparel extended the duration of 
nerve block two-fold compared to 0.5% (w/v) bupivacaine HCl (approximately 10 mg 
per kg total dose of bupivacaine per injection). Animals receiving bupivacaine had a 
median sensory nerve blockade of 120 [120-165] minutes (median [interquartile range]) 
compared to 240 [240- 240] minutes with 0.6 mL of Exparel (approximately 25 mg/kg 
total dose of bupivacaine per injection) 41. McAlvin et al. also compared this dose of 
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Exparel to the equivalent dose of 1.31% (w/v) bupivacaine HCl (approximately 25 mg 
per kg total dose of bupivacaine per injection). This equivalent dose resulted in a sensory 
nerve block lasting 210 [180 – 240] minutes.  
In the preclinical rodent sciatic nerve injection model it is common to use a 
standard injection volume of approximately 300 µl. Therefore, when investigating the 
effects of sex on Exparel mediated sciatic nerve block 300 µl of Exparel (bupivacaine 
concentration of 13.3 mg/ml) was used. This dose contained 4 mg of bupivacaine.  It is 
notable that the preclinical dose-response data is not readily available for Exparel. This 
publication aims to contribute to further understanding this drug by selecting a dose that 
has not been previously studied. 
 
Non-conventional Local Anesthetics 
Despite the improved therapeutic index obtained with drug encapsulation, the use 
of conventional local anesthetics both as a free drug and in encapsulated drug 
formulations are known to cause considerable local tissue reaction. Thus, there is much 
interest in developing nonconventional anesthetic options such as tetrodotoxin (TTX), 
which does not cause local myo- or neurotoxicity42. The site one sodium channel blocker 
(S1SCB), TTX, is an ultrapotent anesthetic that is naturally occurring and is found in 
several organisms, most notoriously, the puffer fish (Fugu) 26 . Unlike bupivacaine, which 
binds to the intracellular domain of the sodium channel, TTX binds to the extracellular 
domain of voltage gated sodium channels.  S1SCBs are very hydrophilic and therefore do 
not bind with high affinity to cardiac myocytes, cross the blood brain barrier, or cross 
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lipid bilayers. Therefore, S1SCBs are less likely to cause seizures or fatal arrhythmias 
like conventional anesthetics. If delivered systemically, TTX can, however, cause 
diaphragmatic paralysis that can lead to respiratory arrest26.  
In small animal studies, TTX has a very narrow therapeutic window. 
Consequently, a dose-response curve for free TTX in a sciatic nerve block animal model 
was consulted prior to dose selection in this study. Injections with 20 µM (2µg) and 40 
µM (4 µg) of TTX, respectively, resulted in few successful blocks (10%), and too high a 
percentage of contralateral blocks (80%) (indicating systemic toxicity). However, in adult 
male rodents, injections with 30 µM (3 µg) TTX resulted in 44% successful nerve block 
with 25% of animals contralateral block 26. Co-injection of TTX with adjuvants, such as 
chemical permeation enhancers and epinephrine, prolong the duration of nerve block and 
decrease systemic side effect26.  
 It is likely that the systemic toxicity associated with TTX would be reduced in 
larger animals, as toxicity of a given dose of anesthetic is directly proportional to the 
volume of distribution of the recipient (much larger in a human than a rat) while local 
anesthetic effect is not 26.  This view is supported by the use of the S1SCB, neosaxitoxin, 
as a local anesthetic in humans, at doses that would be uniformly fatal in small animals 43.  
 Three clinical trials have thus far evaluated the usefulness of TTX as an analgesic. 
The first was an open-label multi-center dose escalation study of TTX in severe cancer-
related pain, in which 24 patients underwent 31 treatment regimens with intramuscular 
TTX. The dose given ranged from 15-90 µg per day and was administered over the 
course of four days. Seventeen of the 31 tested regimens resulted in clinically significant 
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reductions in pain sensitivity, with pain relief persisting for up to two weeks. It was 
concluded that 30 µg twice daily for 4 days was a regimen with an acceptable toxicity 
and analgesic profile 44.  
 Another study tested the same dose (30 µg of TTX administered subcutaneously 
twice daily for 4 days), longitudinally, in a heterogeneous cohort of patients with chronic 
cancer-related pain. These findings demonstrate that TTX has an acceptable tolerability, 
even when administered over a prolonged time period. The toxicity experienced was 
typically mild and was primarily sensory and transient, with peri-oral numbness or 
tingling being the most common symptom. The analgesic effect was sustained in 51% 
(21/41) of patients beyond 12 months, with anti-nociceptive effect for an average of three 
weeks, and no evidence of tolerance.45.  
 Additionally, after years of picturing sodium channels as a single structure, it is 
now known that there are nine sodium channels, each with slightly different structures 
and functions. Three of these channels (Nav1.7, Nav1.8, and Nav1.9) show promise as 
potential pain management drug targets. One Nav1.7 antagonist, raxatigine, is undergoing 
clinical trials for management of trigeminal neuralgia, a chronic pain condition46. These 
studies suggest S1SCB show promise for clinical application and therefore warrant 
testing in animals of both sexes.  
 
Biological Basis for Sex-Related Differences in Pain  
Despite the numerous variables that influence the perception and projection of 
pain (including but not limited to age, ethnicity, family history, gender roles, depression, 
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cognitive and behavioral factors, genetics, hormones, endogenous pain inhibition), 
physiological endpoints, such as pupillary dilation following noxious stimuli, have 
demonstrated an underlying biological distinction in pain perception among males and 
females. When exposed to high-pressure pain stimuli, female subjects experienced 
greater pupil dilations than male counterparts, indicating a difference in pain perception 
that is beyond voluntary control 7. It has also been shown that chronic pain states are 
more common in females than in males from puberty to menopause 8. Of self-reported 
clinical pain, common chronic pain states that are more frequent in women than in men 
include: migraine, fibromyalgia, irritable bowel disorder, temporomandibular disorder, 
and pain associated with rheumatic disease9. Males and females also self-report pain 
differently, in that the prevalence of having at least one of five pain conditions was much 
higher in women aged 18 to 24 years than in men of the same age group. This sexual 
dimorphism decreased with age but was maintained through at least 65 years of age9 . 
Additional studies have validated these findings by showing that female rodents have a 
lower pain threshold in experimental models of thermal47–51 , chemical52–54, 
inflammatory,55–57 and mechanical nociception58,59. Further, Riley et al. describes that the 
pain threshold in women becomes elevated during late pregnancy. However, at all 
hormonal stages, females are more sensitive than males to all types of stimuli.8.  
These studies, in addition to others that investigated differences in clinical 
pain60,61, morphine responsiveness/effect of desired analgesia62, and changes related to 
differences in hormone fluctuation63, suggest a rationale for why males should not be 
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used as proxies for female animals in pain management research. This further highlighted 
a need to determine if there were sex-related differences in response to local anesthetics.   
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METHODS  
 
Animal Care  
Adult male and female Sprague-Dawley rats were obtained from Charles River 
Laboratories (Wilmington, MA) and housed in groups of two per cage on a 7 am to 7 pm 
light/dark cycle. Animals were cared for in accordance with protocols approved by the 
Animal Care and Use Committee at Boston Children’s Hospital, as well as the Guide for 
the Care and Use of Laboratory Animals of the US National Research Council.  
Preparation of Test Solutions  
Bupivacaine hydrochloride (Sigma Chemical Co, St. Louis, MO) was dissolved in 
normal saline solution (0.9% NaCl) to a concentration of 15.4 mM (0.5 wt%, 5 mg/ml). 
Exparel (multivesicular liposomal bupivacaine suspended in 0.9% sodium chloride; 13.3 
mg/ml) was used as received (Pacira Pharmaceuticals, Inc., San Diego, CA).  
Tetrodotoxin (1 mg, >98% purity, Abcam, Cambridge, MA) was dissolved in 10 ml of 20 
mM Citrate buffer (Sodium Citrate: Citrate ratio, 55:45), pH 4.45. The resulting 
tetrodotoxin stock solution (0.1 mg/ml) was then further diluted to a concentration of 30 
M with Phosphate Buffered Saline (PBS). 
Sciatic Nerve Blockade  
Rats were anesthetized using isoflurane in oxygen. All injections were performed 
on the left sciatic nerve, and the right leg served as an untreated, negative control. A 23-
gauge needle was introduced posteromedial to the greater trochanter, pointed in an 
anteromedial direction. Once contact with the bone was established, the solution was 
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injected to deposit drug over the sciatic nerve as described previously26. A volume of 0.3 
mL was used for all injections.  All injections were performed by the same experimenter, 
who demonstrated >99% successful sciatic nerve blocks with 0.1 mL of 0.5% 
bupivacaine before beginning the experiments reported in this study, suggesting that 
differences in successful nerve blockade reflect pharmacological differences rather than 
operator error.  
Sciatic Nerve Blockade Assessment  
In all experiments, the experimenter assessing sciatic nerve block duration was 
blind to the sex of the animal and which treatment the animal had received. Animals that 
did not survive following local injection at the sciatic nerve were not included in the 
duration of the nerve block calculation but were accounted for in the estimation of 
systemic toxicity.  
A modified hot plate test was used to assess blockade of thermal nociception 
(TN). This is a well-accepted method of testing sensory nerve block of the sciatic nerve 
26,64 . Hind paws were exposed in sequence (left then right) in triplicate to a 56°C hot 
plate (model 39D Hot Plate Analgesia meter; IITC Inc., Woodland Hills, CA) with a 10 
second pause in between each trial. Thermal latency was defined as the time (seconds) 
that the animal’s hind paw remained on the hot plate. If the animal did not withdraw the 
hind paw after 12 seconds, the experimenter removed the hind paw in order to prevent 
injury or the development of hyperalgesia. 
 An effective nerve block was defined as a trial that resulted in an average thermal 
latency greater than 7 seconds. This is the duration that corresponds to a half maximal 
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block when a baseline thermal latency of approximately 2 seconds, and a maximal 
latency of 12 seconds are considered. Testing was conducted 30 minutes after injection, 
60 minutes after injection, and every hour thereafter after until nerve block resolution.  
The duration of effective block for TN (duration of sensory blockade) was defined as the 
time (minutes) from the time of injection required for the thermal latency to resolve to an 
average value less than 7 seconds. Data points were taken until nerve blocks were fully 
resolved, in which thermal latencies again resembled baseline values, and were 
comparable to the uninjected, control limb.  
The duration of motor blockade was assessed via the extensor postural thrust 
(EPT) test. During this test, the animal’s hind paws were suspended over a digital scale in 
sequence (left then right) and the amount of weight that it could bear was tested in 
triplicate.  This allowed the examiner to determine the motor strength of the animal’s 
hind paws independently. The maximum weight that the animal could bear without its 
ankle touching the balance was recorded. Animals unable to bear half-maximal body 
weight were considered to have motor block. Data (duration of motor block) was defined 
as the time that it took for weight bearing to return to from maximal to halfway motor 
block. The point of halfway motor block for each rat was determined by the following 
equation:  
 = 	
ℎ − 
ℎ    2 +  
ℎ    # 
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This method of analysis measures the dynamic component of the weight/force 
exerted by the rat, as it subtracts the weight of the limp paralyzed foot from the total force 
exerted26.  
Tissue Harvesting and Histology  
 Four days after injection, animals were euthanized by carbon dioxide. The sciatic 
nerve and surrounding tissue were harvested, fixed in 10% neutral buffered formalin for 
at least 24 hours, and were then stained with hematoxylin and eosin. Histology findings 
were categorized and scored based on inflammation (0-4) and myotoxicity (0-6).  
Inflammatory reaction was scored on a scale of 0-4 (normal – severe inflammation). 
Myotoxicity was scored by the amount of nuclear internalization and regeneration of 
present myocytes, as these are two factors common to local anesthetic myotoxicity. 
Nuclear internalization was characterized as myocytes having nuclei located differently 
from their usual location on the cells periphery. Regeneration was characterized by the 
presence of shrunken myocytes with basophilic cytoplasm. The scoring scale was: 0 = 
normal; 1= perifascicular internalization; 2 = deep internalization (more than five cell 
layers); 3 = perifascicular regeneration; 4 = deep tissue regeneration (more than five cell 
layers); 5 = hemifascicular regeneration; 6 = holofascicular regeneration 65.  
Statistical Analysis  
Non-parametric data (duration of nerve blockade, baseline thermal latency, and 
histological scoring) were presented as medians with interquartile ranges and were 
evaluated by Mann-Whitney U statistically analysis. Parametric data (incidence of 
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contralateral block, respiratory distress, and mortality) were presented as percentages and 
part of whole and were statistically analyzed by performing a comparison of population 
proportions, with an alpha of 0.05. All analyses were performed using GraphPad Prism 
version 7 for Mac OS X (GraphPad Software, San Diego, CA), and p < 0.05 was 
considered statistically significant. 
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RESULTS 
 
Determination of baseline thermal latency for male and female rats  
 Adult male Sprague-Dawley rats will remove their hind paws from a hotplate 
within 2-3 seconds of a modified hotplate test (see Methods)26. It is commonly accepted 
that female rodents have a lower baseline thermal latency than male rodents47–51. 
However, the baseline thermal latency of female rats after exposure to the modified hot 
plate test is unknown. To test this, the hind paws of male and female rats were exposed in 
sequence (left then right) to a hot plate set at 56 °C and the time until the paw was 
withdrawn was measured as thermal latency. Data from 12 males and 12 females were 
compiled.  
 Male rodents withdrew their hind paws at a time of 3.17 [2.64 - 4.03] (median 
[interquartile range]) seconds, consistent with what has been described in previous 
reports26. Female rodents had a statistically shorter median baseline thermal latency of 
2.62 [2.13 - 3.16] seconds, as calculated by the Mann-Whitney U statistical test, p< 
0.0001 (Figure 1), an approximately 21% difference.  
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Figure 1. Determination of baseline thermal latency for male and female rats. Modified 
hot plate testing was performed on male (n=12) and female (n=12) rodents. Time to 
hindpaw withdrawal was measured. Data presented as medians with interquartile ranges. 
**** p < 0.0001 by Mann-Whitney U test.  
 
The effect of bupivacaine mediated sciatic nerve blockade in male and female rats  
 To investigate the role of sex as a determining factor for the effect of bupivacaine 
on sciatic nerve block, male and female rats were injected at the sciatic nerve with 300 μl 
of 0.5% bupivacaine and underwent neurobehavioral testing (see Methods) to determine 
sensory (nociception, perception of pain) and motor (weight bearing) nerve block. All 
animals were weighed before treatment, and four animals of each sex were used. The raw 
thermal latency data collected were used to calculate duration of sensory nerve block, 
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motor nerve block, percentage of successful nerve block, and to study the incidence of 
systemic effects. 
 There was a lack of sexual dimorphism for the duration of sensory nerve 
blockade. Males had a nerve block lasting 162.2 [145.2 - 188.0] minutes compared to 
161.2 [141.0 – 173.7] minutes in female rodents (Figures 2A). Similarly, there was no 
statistically significant difference in duration of motor block between male and female 
animals. Male rats had a median duration motor blockade of 173.3 [146.2 - 216.0] 
minutes and female rats 157.4 [138.0 – 174.1] minutes (Figure 2B). 
 In this experimental group, there was a notable difference in the animal weights, 
in that female rats were significantly smaller than male rats. Male rodents had a median 
weight of 375 [359 - 389] grams and female median weight was 303.5 [303 - 316] grams, 
(p = 0.03). To determine if animal weight affected block duration, the duration of sensory 
or motor nerve block was plotted against animal weight for each animal tested. A 
correlation did not exist between animal weight and block duration for adult male and 
female rodents (Figures 2C, D). This finding, that animal weight did not affect block 
duration, is consistent with studies in adolescent and adult male rodents (with more than 
an eightfold difference in weight), which had a similar duration of sensory and motor 
nerve blockade when treated with 0.5% bupivacaine at the sciatic nerve43. It is notable, 
however, that this study did reveal a significant difference in duration of sensory nerve 
block between infant and adolescent rodents which have a 2.3 fold difference in weight. 
Perhaps suggesting that large weight differences affect block duration or highlight the 
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fundamental differences in drug metabolism or even differences in peripheral nerve 
myelination between these age ranges. 
 
 
 
Figure 2. The effect of bupivacaine mediated sciatic nerve blockade in male and female 
rats. (A) Duration of sensory nerve block, and (B) duration of motor nerve block; data 
are medians with interquartile ranges; n=4 for each treatment group. (C) Duration of 
sensory nerve block versus animal weight and (D) duration of motor nerve block versus 
animal weight; data is plotted for each animal tested; n=4 for each treatment group.  
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The effect of Exparel mediated sciatic nerve blockade in male and female rats   
 To investigate the role of sex as a determinant for Exparel’s effect on sciatic nerve 
block, male and female rats were injected at the sciatic nerve with 300 μl of 13.3 mg/ml 
liposomal bupivacaine (Exparel) (4 mg of bupivacaine in injected solution) and 
underwent neurobehavioral testing (see Methods) to determine sensory (nociceptions, 
perception of pain) and motor (weight bearing) nerve block. These data were used to 
calculate duration of sensory and motor nerve block, percentage of successful nerve 
block, and studied incidence of systemic effects. Five male animals and seven female 
animals were used in this treatment group. All animals were weighed prior to 
experimentation.  
There was no statistically significant difference in the duration of sensory or 
motor nerve block between male and female rodents. Male rodents injected with Exparel 
had a sensory nerve block of 232.0 [217.1 – 308.7] minutes (n=5), and 306.8 [249.4 – 
348.4] (n=7) minutes for female rodents  (Figure 4A). The duration of motor nerve block 
was 270 [225.0 – 322.3] minutes for males compared to 330.3 [261.5 – 380.5] minutes 
(Figure 4B).  
In this cohort, the difference in weight between the male (410 [331- 412] grams) 
and female (305 [260 – 365] grams) animals was not statistically significant. When 
plotting the duration of sensory block versus animal weight in females, there appears to 
be a trend towards negative correlation, suggesting that animals of smaller weights 
experience longer duration of sensory blockade.  However, this relationship is not 
apparent for motor blockade.  
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Figure 3. The effect of Exparel mediated sciatic nerve blockade in male and female rats. 
Effect of Exparel mediated (A) sensory and (B) motor block duration. Data are medians 
with interquartile ranges. Duration of (C) sensory nerve block versus animal weight and 
(D) motor nerve block versus animal weight received is plotted for each animal tested, 
(males n=5 and females, n=7)  
The effect of TTX mediated sciatic nerve blockade in male and female rats  
 To investigate the role of sex as a determinant for TTX effects on sciatic nerve 
block, male and female rats were injected at the sciatic nerve with 300 μl of 30 μM TTX 
and underwent neurobehavioral testing (see Methods) to determine sensory (nociception, 
perception of pain) and motor (weight bearing) nerve block. Twelve male and ten female 
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rats were injected. Ten animals of each sex survived the injection and were subsequently 
tested. These data were used to calculate duration of sensory and motor nerve block, 
percentage of successful nerve block, and studied incidence of systemic effects. All 
animals were weighed prior to experimentation.  
Unlike other treatment groups, not all injections resulted in successful nerve 
blockade, as has been reported previously for this compound26.  Our reported data, 
therefore, spans a large range due to the fact that all unsuccessful blocks were included in 
the analysis as having a duration of zero minutes. Even so, there was no difference in the 
duration of sensory or motor nerve block between male and female animals. The median 
duration of sensory blockade was 59.6 [17.4– 116.8] minutes for males and 57.02 [32.8 – 
121.8] minutes for females (Figure 3A).  Similarly, the duration of motor nerve block 
was 82.3 [40.1 – 112.2] minutes for males and 78.64 [32.2 – 142.5] minutes for females 
(Figure 3B).  
In this treatment group, the difference in weight between the male and female 
animals was not statistically significant; males weighed 310 [304 – 401] grams and 
females weighed 312 [302 – 330] grams. To determine if animal weight contributed to 
the large range of block duration observed, animal weight was plotted against the 
duration of sensory nerve block or duration of motor nerve block for each animal tested. 
A correlation was not observed between animal weight and duration of sensory or motor 
nerve blockade, in that duration of block varied over a wide range for animals (male and 
female) of similar weights (Figures 3C, D). This can be explained by the 
pharmacokinetics of TTX, a hydrophilic molecule, which even with local injection has 
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difficulty crossing the epineurium, resulting in unsuccessful and inconsistent nerve 
block7. 
 
 
Figure 4. The effect of TTX mediated sciatic nerve blockade in male and female rats. 
 (A) Duration of sensory nerve block, (B) duration of motor nerve block, Data are 
medians with interquartile ranges; n=10 for each treatment group. (C) Duration of 
sensory nerve block versus animal weight and (D) duration of motor nerve block versus 
animal weight is plotted for each animal tested. Data for each animal tested is plotted; 
n=10 for each treatment group. 
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Systemic effects of treatments  
Systemic effects after local injection, such as contralateral nerve block, 
respiratory distress, and/or death, suggest the drug has been systemically distributed. All 
animals were assessed for signs of systemic effects (contralateral block, respiratory 
distress, death). None of the male or female animals injected with 0.5% bupivacaine, or 
Exparel had evidence of these systemic effects (Table 1).  Symptoms associated with 
systemic toxicity were observed in animals injected with TTX. In previously published 
studies, 25% of male rodents injected with 30 µM TTX had evidence of contralateral 
nerve block. In this study, contralateral block was observed in 70% of male rodents, and 
in 50% of female rodents. Respiratory distress was observed in 50% of males and 40% of 
female rodents. Injection with TTX resulted in death for 17% of male rodents, but did not 
result for any female rodents. There was no statistically significant difference for these 
variables between male and female rodents (Table 1).  
 
Table 1. Systemic effects of treatment 
Treatment 
*Bupivacaine  §Exparel  ¶Tetrodotoxin 
Male Female p value Male  Female  p value Male  Female  p value  
Contralateral 
Block (%) 
0 
(0/4) 
0 
(0/4) 
0.99 
0 
(0/5) 
0 
(0/7) 
0.99 
70 
(7/10) 
50 
(5/10) 
0.36 
Respiratory 
Distress (%) 
0 
(0/4) 
0 
(0/4) 
0.99 
0 
(0/5) 
0 
(0/7) 
0.99 
50 
(6/12) 
40 
(4/10) 
0.64 
Mortality (%) 
0 
(0/4) 
0 
(0/4) 
0.99 
0 
(0/5) 
0 
(0/7) 
0.99 
17 
(2/12) 
0  
(0/10) 
0.18 
 
*Bupivacaine hydrochloride dose  = 15.4 mM = 0.5% = 1.5 mg; §Exparel dose = 4 mg; 
¶Tetrodotoxin dose = 30 μM = 3 μg. 
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Tissue reaction to treatments  
Tissue reaction was assessed by examination of hematoxylin-eosin stained sections of 
the injection site, containing adjacent nerve and surrounding muscle, 4 days after 
injection. This time point reflects the period required for the development of acute 
inflammation and the progression of myotoxicity. Representative hematoxylin and eosin 
stained tissues at the site of injection 4 days following injection are shown to highlight 
the mild inflammation and myotoxicity appreciated (Figure 5).  
Each hematoxylin-eosin section was then scored for myotoxicity and inflammation 
as described (see Methods). Scoring was performed on three male and three female 
animals per treatment group (Figure 5). Animals treated in all three groups showed had 
minimal inflammation (score of 1 out of 4) and no myotoxicity (score 0 out of 6) at 4 
days after injection. There was no statistically significant difference in any of the groups 
that were treated and examined.  
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Male               Female  
Figure 5. Representative light microscopy images of hematoxylin and eosin stained 
sections of sciatic nerve (SN) and surrounding tissues (muscle (M)) at the site of injection 
of (A, B) 0.5% bupivacaine, (C, D) 4 mg Exparel, and (E, F) 30 µM TTX.  Sciatic nerve 
and surrounding tissues were harvested 4 days after injection. Left panels show male and 
right panels show female sciatic nerves and surrounding tissues.  
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DISCUSSION 
 
 While males and females experience pain differently, it was unknown whether 
biological sexual dimorphisms exist in response to local anesthetics. In this study, an 
animal model of sciatic nerve blockade was used to examine the male and female rodent 
response to local anesthetics. One representative drug from different classes of local 
anesthetics was studied; including a conventional amide local anesthetic (bupivacaine), a 
site one sodium channel blocker (tetrodotoxin), and the commercially available liposomal 
bupivacaine formulation (Exparel). Block success, sensory and motor nerve block 
duration, as well as local and systemic toxicity were measured. No sexual dimorphism 
was appreciated in any of the treatments tested; indicating that for these particular local 
anesthetics, male rodents may accurately serve as proxies for female rodents in this pre-
clinical model. 
 This study validated the well-accepted idea that male and female rodents differ in 
their baseline pain thresholds, in that female rodents are more sensitive to thermal pain 
than males (Figure 1) 47–51. Although the median baseline thermal latency values between 
male and female rodents differed, these values did not deviate substantially from the 
assumed baseline thermal latency value (2-3 seconds). This assumed value is an 
important part of the interpretation of thermal latency data. Had the median male and 
female baseline thermal latency data deviated significantly, the definitions of: successful 
block, midpoint time for block resolution, duration of sensory block, and duration of 
motor nerve block, would have been affected.  
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While it was found that male and female rodents do not differ in their response to 
local anesthetics, limitations to this study are recognized. Previous studies have suggested 
that the female rodents’ pain threshold may correlate with progesterone levels, in that for 
pressure stimulation, cold pressor pain, thermal heat stimulation, and ischemic muscle 
pain, it is highest when progesterone levels peak8. In this study, female rodents were 
tested across their entire estrous cycle, without hormonal data to indicate which stage of 
the cycle they were in during experimentation. It is therefore possible that if female 
rodents with low progesterone levels (and therefore perhaps lower pain threshold) were 
tested, the outcomes of this study may have differed.  However, within the field of sex, 
gender, and pain research, there is much debate over whether or not testing female 
rodents at specific stages of their estrous cycle is valuable. For example, in rodents, large 
sample sizes are often needed to adequately power studies that examine the specific 
stages of the estrous cycle, as hormonal influence is not indicated by variance. 
Additionally, the determination of hormonal influence is labor intensive, requiring that 
females be handled and probed daily for at least 2 estrous cycles (8-10 days) to monitor 
hormone levels via vaginal cytology sampling. It is also known that male and female 
rodents respond differently to acute stressors, in that the endogenous opioid system, 
(which can be triggered by stress, pain, or pleasure), of female rats produces analgesia to 
a lesser extent. It is therefore unclear if the handling required to investigate female 
hormonal levels would create another confounding variable, and even if males were 
handled for the same amount of time, it is unknown if their stress response would be the 
same66.  
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 Sample size varied across treatment groups and was generally small (4 to 10 
animals per group). If sample size were increased to include hundreds of male and female 
rodents, it is possible that the results of this study could differ. However, we were 
interested in detecting effects that were likely to be of clinical significance (a 25% 
difference should be detectable with n = 4), not in detecting even very small differences. 
Moreover, the block durations achieved for each local anesthetic studied were similar to 
what has been previously reported in the literature.  
 The number of data points gathered, as well as, the time points at which data was 
collected may have also limited the findings in this study. For example, if male and 
female rats were tested more frequently, immediately after injection (rather than starting 
data collection 30 minutes after injection), data could be gathered about the duration of 
anesthetic onset. A similar approach could then be taken as block resolution approached, 
to determine the duration and rate of sensation recovery. These data were not collected in 
fear that more frequent testing would result in tissue injury and/or hyperalgesia. 
However, this data could provide more valuable insight towards any sex-related 
difference in pharmacological mechanisms of drug efficacy.  
There are many different formulations that could have been tested to investigate 
the potential sexual dimorphism in response to local anesthetics. For this study, the 
conventional amide local anesthetic (bupivacaine), the non-conventional local anesthetic 
S1SCB (tetrodotoxin), and the liposomal bupivacaine formulation (Exparel) were chosen. 
Future studies could investigate if other drug delivery vehicles or categories of local 
anesthetics have different mechanisms between male and female rodents. This group 
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plans to investigate other drug formulations such as those that are triggerable (with light 
and/or ultrasound), contain drug via conjugation or hydrogels, and are composed of 
different polymers.  Additionally, only one injection site (sciatic nerve) was tested for 
analgesic response and duration. It is therefore possible that a difference may exist 
between male and female rodents at another peripheral nerve block site.  
 Upon experimentation, there was a notable difference between the weights of 
male and female animals. Despite an attempt to create treatment groups with animals of 
the same approximate weight, doing so was difficult as the growth curves of male and 
female Sprague-Dawley rats differ. Animals were ordered at weights that are typically 
reported in the literature (300-350g), but upon arrival, male animals grew rapidly, often 
surpassing the heaviest female before injection and testing were conducted. Upon this 
realization, male rats were ordered at a lower weight (250-300g) in hope of creating 
treatment groups consisting of animals at the same approximate weight. Despite our best 
efforts, a statistically significant difference between the weights of animals existed in the 
bupivacaine treatment group. However, although this statistically significant difference 
was present, no difference in durations of anesthesia between male or female animals was 
appreciated.  
Although local anesthetics are not often dosed by weight to evaluate the duration 
of effective nerve block, it is crucial to consider the weight of the subject when 
evaluating toxicity, or when working with certain patient populations; specifically 
pediatric patients. Given the weight differential between male and female animals here, 
this study hoped to understand the role that weight may play in extending or shortening 
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the duration of local anesthesia. There was concern that a difference in weight between 
male and female rodents may cause a longer duration of blockade, due to female rodents 
theoretically receiving a higher mg/kg dose of drug compared to male counterparts. In an 
attempt to understand if animal weight affected block duration, these variables were 
plotted for all animals tested. For bupivacaine and TTX, a correlation between animal 
weight and block duration was not observed. Notably, the median durations of sensory 
and motor nerve block were similar for these anesthetics. For Exparel, there seemed to be 
a trend towards smaller animals experiencing longer block durations. To study this 
further, the sample size will need to be increased, and dose-response testing should be 
completed for this drug. Of note, formal dose response data that uses hot plate testing as 
an endpoint for anesthetic effect is not readily available in a pre-clinical model for 
Exparel.  
Larger, more comprehensive studies may be warranted to continue the 
investigation of whether or not different categories of local anesthetics and prolonged 
duration local anesthetic formulations create different durations of sensory and motor 
nerve block, percent successful blocks, and incidences of systemic toxicities between 
male and female rodents. Previous works have established a rationale for sex, gender, and 
pain studies and despite a negative result for the three drugs tested in this study, it is 
possible that there is an underlying biological difference at other levels of observation (i.e 
gene expression, receptor density). Despite the numerous variables that influence the 
perception and projection of pain (including but not limited to age, ethnicity, family 
history, gender roles, depression, cognitive and behavioral factors, genetics, hormones, 
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endogenous pain inhibition), a number of studies have clearly illustrated an underlying 
biological basis for the higher prevalence of chronic pain and greater pain sensitivity that 
has been noted in women. For example, a large and rapidly increasing body of evidence 
indicates that microglia-neuron signaling is essential for chronic pain hypersensitivity, 
but that microglia are not required for mechanical pain hypersensitivity in female mice. 
Instead, female mice achieve a similar level of pain hypersensitivity using the adaptive 
immune system, likely via T-lymphocytes67. Evidence for sex-related differences 
between male and female response and sensitivity to pain has also been reported at the 
level of gene expression. Korczeniewska et al. investigated the gene expression changes 
in the trigeminal ganglia of male and female rats that were exposed to infraorbital nerve 
chronic constriction injury. Thus showing sex dependent gene regulation in response to 
nerve injury, a possible explanation for sexual dimorphism among male and female 
subjects with trigeminal neuropathic pain68.  
Similarly, there is an increased prevalence of bladder pain syndromes in female 
research subjects compared to males, prompting the hypothesis that estrogen may play a 
role in this pathophysiology of interstitial cystitis. It has been shown that patients with 
interstitial cystitis have increased levels of substance P-containing sensory nerves in the 
bladder submucosal region, which contributes to neurogenic inflammation.  Several 
members of the transient receptor potential (TRP) ion channel family are found in the 
bladder and may participate in bladder physiology and pathophysiology. Sensory nerves 
innervating the bladder suburoethelial layers (lamina propria) express several nociceptive 
TRP channels including TRPV1, which is the capsacasin receptor – the most prominent 
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receptor in pain signaling pathway. This group found that the number of TRPV1 positive 
arterial/arteriolar smooth muscle cells (ASM) rings per unit length was significantly 
greater in females compared to males69. It is possible that the biological difference in 
density of TRPV1 receptors between male and female rats may lead to significant 
difference in the duration of anesthesia yielded by capsaicin or lidocaine-N-ethyl-
bromide (QX-314). Further research could help characterize local anesthetics that are 
known to act at this receptor, specifically capsaicin and the chemical permeation 
enhancer, QX-314.  
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